M. A. Climent Duran - Dept Med Oncol, Fdn Inst Valenciano Oncol

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 23 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1601P First Results from ZZFIRST: A Randomized Phase II Trial of Enzalutamide (EZ) with or Without Talazoparib (TALA) in Metastatic Hormone-Naïve Prostate Cancer (Mhnpc)

J. Mateo, E. Castro,A. Rodriguez-Vida,B. Mellado Gonzalez,D.E. Castellano Gauna,M.A. Climent Duran, A. Borque Fernando,M.I. Sáez,B. Herrera Imbroda,A. Font Pous, D. Lorente, J. Planas Morin, A. Vivancos, J. Cardona, J.A. Guerrero, J. Perez-Escuredo, A.J. Zurita Saavedra, J.C. Galceran

Annals of Oncology (2024)

引用0浏览0引用

1791P Molecular Profiling and Prognostic Relevance of Low PTEN Expression in Metastatic Hormone-Sensitive Prostate Cancer Patients

M. Garcia De Herreros, N. Jimenez Blasco,O. Reig Torras,V. Ruiz de Porras,J. C. Pardo,A. Font Pous,C. Aversa, L. Ferrer-Mileo, M. Jorda,L. Rodriguez-Carunchio, I. Trias Puigsureda,A. Sanchez-Font,A. Rodriguez-Vida,M. Domenech Santasusana,M. Figols Gorina,M. A. Climent Duran,I. Chirivella Gonzalez,D. Herrero Rivera,E. Gonzalez Billalabeitia,B. Mellado Gonzalez

Annals of Oncology (2023): S968-S968

引用0浏览0引用

1783P PROSTRATEGY: A SOGUG Randomized Trial of Androgen Deprivation Therapy (ADT) Plus Docetaxel (dct) +/- Nivolumab (nivo) or Ipilimumab-Nivolumab (Ipi-Nivo) in High-Volume Metastatic Hormone-Sensitive Prostate Cancer (hvhspca) - Efficacy Results from the Pilot Phase

J. A. Arranz Arija,J. M. Piulats Rodriguez,S. Vazquez Estevez,J. M. Sepulveda Sanchez,T. Alonso Gordoa,B. Perez Valderrama,N. Sala Gonzalez,M. A. Climent Duran,E. Gallardo Diaz,A. Rodriguez-Vida,C. Caballero Diaz,J. Puente,M. J. Mendez Vidal, E. M. F. Parra, R. C. Martin,J. A. Virizuela Echaburu, M. B. G. Gragera,J. Garcia Sanchez,I. Garcia-Carbonero,J. Carles Galceran

Annals of oncology (2023): S963-S964

引用0浏览0引用

2366P Phase I-II Study of Niraparib Plus Cabozantinib in Patients with Advanced Urothelial/kidney Cancer (NICARAGUA Trial)

D.E. Castellano Gauna,I. Duran Martinez,B. Mellado González,Miguel Á. Climent Durán, Xavier García del Muro,N. Sala González,Teresa Alonso Gordoa,E. Sevillano Fernandez,Montserrat Domènech Santasusana,Jesús M. Paramio,Francisco X. Real,Núria Malats,Albert Font Pous

Annals of Oncology (2023): S1204-S1204

引用0浏览0引用

2371P Avelumab First-Line (1L) Maintenance for Advanced Urothelial Carcinoma (auc): Long-term Outcomes from the JAVELIN Bladder 100 Trial in Older Patients (Pts)

S. Gupta,M.A. Climent Duran, S. Sridhar,T.B. Powles,J. Bellmunt, K. Tyroller,S. Guenther,A. di Pietro,P. Grivas

Annals of Oncology (2023): S1207

引用0浏览0引用

1448O Phase II KEYNOTE-B61 Study of Pembrolizumab (pembro) + Lenvatinib (lenva) As First-Line Treatment for Non-Clear Cell Renal Cell Carcinoma (Nccrcc)

L. Albiges,H.P. Gurney, V. Atduev, C. Suárez,M.A. Climent Duran,D. Pook,P. Tomczak, P. Barthelemy,J-L. Lee, T. Nalbandian,V. Stus, T. Ferguson,P. Wiechno,E. Gokmen,L. Lacombe,C. Gedye, R. Perini, M. Sharma, C. Li,C-H. Lee

Annals of Oncology (2022)

引用0浏览0引用

Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) plus lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)

L. Albiges,H. P. Gurney, V. Atduev,C. Suarez,M. A. Climent Duran,D. Pook,P. Tomczak,P. Barthelemy,J-L. Lee, T. Nalbandian,V. Stus, T. Ferguson,P. Wiechno,E. Gokmen,L. Lacombe,C. Gedye,R. Perini, M. Sharma, C. Li,C-H. Lee

ANNALS OF ONCOLOGYno. 7 (2022): S1204-S1204

引用0浏览0引用

666P Pembrolizumab (pembro) Monotherapy As First-Line Therapy in Advanced Clear Cell Renal Cell Carcinoma (ccrcc): Results after a Minimum of 41 Months of Follow-Up from KEYNOTE-427 Cohort A

D. F. McDermott,J-L. Lee,G. A. Bjarnason,J. Larkin,R. Gafanov, M. D. Kochenderfer,N. V. Jensen,F. Donskov, J. Malik,A. Poprach,S. S. Tykodi,T. Alonso-Gordoa,D. C. Cho,P. F. Geertsen,M. A. Climent Duran, C. Di Simone,H. Liu,J. Burgents,K. Rodriguez-Lopez,M. B. Atkins

Annals of oncology (2021): S691-S692

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn